Orbimed Advisors - Q2 2023 holdings

$5.52 Billion is the total value of Orbimed Advisors's 127 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 29.0% .

 Value Shares↓ Weighting
SVA  SINOVAC BIOTECH LTD$340,000,0000.0%2,718,7350.0%6.16%
-7.7%
ISRG  INTUITIVE SURGICAL INC$212,173,770
+33.8%
620,5000.0%3.84%
+23.5%
BuyENLIVEN THERAPEUTICS INC$183,656,079
-6.8%
8,998,338
+0.0%
3.33%
-14.0%
BSX SellBOSTON SCIENTIFIC CORP$182,818,791
-3.6%
3,379,900
-10.8%
3.31%
-11.0%
 THESEUS PHARMACEUTICALS INC$160,790,122
+5.1%
17,233,6680.0%2.91%
-3.0%
BIIB BuyBIOGEN INC$158,604,480
+13.0%
556,800
+10.3%
2.87%
+4.3%
HUM  HUMANA INC$155,914,231
-7.9%
348,7000.0%2.82%
-15.0%
BAX BuyBAXTER INTL INC$153,765,000
+142.7%
3,375,000
+116.1%
2.79%
+124.0%
BMRN  BIOMARIN PHARMACEUTICAL INC$140,006,403
-10.9%
1,615,2100.0%2.54%
-17.7%
UNH SellUNITEDHEALTH GROUP INC$117,276,160
-10.1%
244,000
-11.6%
2.12%
-17.0%
EWTX  EDGEWISE THERAPEUTICS INC$112,895,614
+16.2%
14,567,1760.0%2.05%
+7.3%
NewACELYRIN INC$111,319,7125,326,302
+100.0%
2.02%
SWTX SellSPRINGWORKS THERAPEUTICS INC$109,562,577
-5.4%
4,178,588
-7.1%
1.98%
-12.7%
 DISC MEDICINE INC$100,771,883
+109.5%
2,269,6370.0%1.83%
+93.4%
BMY SellBRISTOL-MYERS SQUIBB CO$95,157,600
-41.3%
1,488,000
-36.4%
1.72%
-45.9%
IONS BuyIONIS PHARMACEUTICALS INC$89,014,585
+17.2%
2,169,500
+2.1%
1.61%
+8.2%
UTHR NewUNITED THERAPEUTICS CORP DEL$88,719,425401,900
+100.0%
1.61%
EVH  EVOLENT HEALTH INCcl a$87,737,650
-6.6%
2,895,6320.0%1.59%
-13.8%
VECT  VECTIVBIO HLDG AG$87,661,537
+99.8%
5,156,5610.0%1.59%
+84.4%
LLY  LILLY ELI & CO$87,230,280
+36.6%
186,0000.0%1.58%
+26.1%
TMO BuyTHERMO FISHER SCIENTIFIC INC$84,940,900
-0.3%
162,800
+10.1%
1.54%
-8.0%
APLS  APELLIS PHARMACEUTICALS INC$82,919,220
+38.1%
910,2000.0%1.50%
+27.4%
SYK SellSTRYKER CORPORATION$82,801,426
-21.1%
271,400
-26.2%
1.50%
-27.2%
VRNA SellVERONA PHARMA PLCsponsored ads$79,862,227
-6.7%
3,777,778
-11.3%
1.45%
-13.9%
THC SellTENET HEALTHCARE CORP$78,165,490
+7.8%
960,500
-21.3%
1.42%
-0.5%
SRPT SellSAREPTA THERAPEUTICS INC$74,896,080
-37.2%
654,000
-24.4%
1.36%
-42.0%
MDGL NewMADRIGAL PHARMACEUTICALS INC$74,282,439321,569
+100.0%
1.35%
CRNX  CRINETICS PHARMACEUTICALS IN$71,193,344
+12.2%
3,950,7960.0%1.29%
+3.5%
CMPX  COMPASS THERAPEUTICS INC$71,113,863
-2.8%
22,362,8500.0%1.29%
-10.2%
XTNT  XTANT MED HLDGS INC$67,989,259
+45.9%
73,114,5920.0%1.23%
+34.6%
TERN  TERNS PHARMACEUTICALS INC$66,667,431
-26.1%
7,619,1350.0%1.21%
-31.8%
 PRELUDE THERAPEUTICS INCnonvoting$66,334,294
+23.3%
11,895,6520.0%1.20%
+13.7%
BuyR1 RCM INC$63,486,450
+141.9%
3,441,000
+96.6%
1.15%
+123.3%
SIBN SellSI-BONE INC$61,852,486
+7.7%
2,292,531
-21.5%
1.12%
-0.5%
KROS SellKEROS THERAPEUTICS INC$60,862,012
-15.1%
1,514,734
-9.8%
1.10%
-21.7%
SBTX  ARS PHARMACEUTICALS INC$58,563,943
+2.9%
8,740,8870.0%1.06%
-5.0%
VRTX SellVERTEX PHARMACEUTICALS INC$58,205,914
+4.0%
165,400
-6.9%
1.06%
-3.9%
SCPH  SCPHARMACEUTICALS INC$56,651,590
+12.3%
5,559,5280.0%1.03%
+3.6%
SNDX BuySYNDAX PHARMACEUTICALS INC$52,957,923
+46.5%
2,530,240
+47.8%
0.96%
+35.2%
PCVX BuyVAXCYTE INC$50,296,971
+84.0%
1,007,148
+38.1%
0.91%
+69.6%
PRLD BuyPRELUDE THERAPEUTICS INC$49,091,652
-14.2%
10,909,256
+8.7%
0.89%
-20.7%
EW SellEDWARDS LIFESCIENCES CORP$48,579,950
-6.8%
515,000
-18.3%
0.88%
-14.0%
NTRA  NATERA INC$47,374,451
-12.4%
973,5810.0%0.86%
-19.1%
NBIX  NEUROCRINE BIOSCIENCES INC$46,112,700
-6.8%
489,0000.0%0.84%
-14.0%
CI NewTHE CIGNA GROUP$45,176,600161,000
+100.0%
0.82%
XENE SellXENON PHARMACEUTICALS INC$42,196,000
+2.6%
1,096,000
-4.6%
0.76%
-5.2%
ALPN  ALPINE IMMUNE SCIENCES INC$41,958,766
+33.2%
4,081,5920.0%0.76%
+22.8%
PMVP  PMV PHARMACEUTICALS INC$41,084,862
+31.2%
6,563,0770.0%0.74%
+21.0%
ZBH NewZIMMER BIOMET HOLDINGS INC$35,672,000245,000
+100.0%
0.65%
RPTX  REPARE THERAPEUTICS INC$35,151,923
+7.5%
3,322,4880.0%0.64%
-0.8%
GRCL SellGRACELL BIOTECHNOLOGIES INCsponsored ads$34,418,496
+94.8%
9,033,726
-4.9%
0.62%
+79.8%
JANX  JANUX THERAPEUTICS INC$33,667,902
-1.9%
2,836,3860.0%0.61%
-9.5%
IOVA  IOVANCE BIOTHERAPEUTICS INC$33,140,504
+15.2%
4,707,4580.0%0.60%
+6.2%
MRTX  MIRATI THERAPEUTICS INC$33,010,175
-2.8%
913,6500.0%0.60%
-10.3%
HZNP BuyHORIZON THERAPEUTICS PUB L$32,541,740
+49.1%
316,400
+58.2%
0.59%
+37.5%
TVTX BuyTRAVERE THERAPEUTICS INC$32,534,016
-17.1%
2,118,100
+21.4%
0.59%
-23.4%
TELA SellTELA BIO INC$28,724,040
-10.8%
2,835,542
-6.3%
0.52%
-17.7%
AMGN BuyAMGEN INC$28,263,146
+52.4%
127,300
+66.0%
0.51%
+40.7%
VERA BuyVERA THERAPEUTICS INCcl a$28,196,640
+166.7%
1,756,800
+28.9%
0.51%
+145.7%
 THIRD HARMONIC BIO INC$27,797,332
+16.7%
5,779,0710.0%0.50%
+7.9%
ABCL  ABCELLERA BIOLOGICS INC$27,007,761
-14.3%
4,180,7680.0%0.49%
-21.0%
KNTE BuyKINNATE BIOPHARMA INC$24,269,479
-24.5%
8,009,729
+55.7%
0.44%
-30.3%
 2SEVENTY BIO INC$24,203,275
-0.8%
2,391,6280.0%0.44%
-8.4%
MRSN SellMERSANA THERAPEUTICS INC$23,737,143
-35.9%
7,214,937
-19.9%
0.43%
-40.9%
QURE  UNIQURE NV$23,658,654
-43.1%
2,064,4550.0%0.43%
-47.4%
RAPT  RAPT THERAPEUTICS INC$23,395,009
+1.9%
1,251,0700.0%0.42%
-6.0%
FOLD BuyAMICUS THERAPEUTICS INC$23,316,384
+79.5%
1,856,400
+58.5%
0.42%
+65.5%
ALXO  ALX ONCOLOGY HLDGS INC$21,561,210
+66.2%
2,871,0000.0%0.39%
+53.3%
IKNA  IKENA ONCOLOGY INC$20,901,249
+90.1%
3,186,1660.0%0.38%
+75.5%
ACET BuyADICET BIO INC$20,222,800
-52.9%
8,322,140
+11.7%
0.37%
-56.5%
DBTX  DECIBEL THERAPEUTICS INC$19,038,989
+27.5%
4,945,1920.0%0.34%
+17.7%
ARQT  ARCUTIS BIOTHERAPEUTICS INC$18,244,985
-13.4%
1,914,4790.0%0.33%
-19.9%
NPCE  NEUROPACE INC$18,015,142
-3.2%
4,012,2810.0%0.33%
-10.7%
SellVENTYX BIOSCIENCES INC$17,744,275
-9.5%
540,984
-7.5%
0.32%
-16.4%
CRVS  CORVUS PHARMACEUTICALS INC$15,900,968
+151.6%
6,943,6540.0%0.29%
+132.3%
FUSN  FUSION PHARMACEUTICALS INC$14,583,336
+23.9%
3,122,7700.0%0.26%
+14.3%
XFOR BuyX4 PHARMACEUTICALS INC$13,839,019
+173.4%
7,133,515
+22.6%
0.25%
+153.5%
BAX SellBAXTER INTL INCcall$13,668,000
-3.7%
300,000
-14.3%
0.25%
-11.1%
KZR  KEZAR LIFE SCIENCES INC$13,384,350
-21.7%
5,463,0000.0%0.24%
-27.7%
AVTE  AEROVATE THERAPEUTICS INC$12,981,350
-15.0%
756,9300.0%0.24%
-21.7%
ARGX SellARGENX SEsponsored adr$12,705,198
-23.4%
32,600
-26.7%
0.23%
-29.2%
MORF NewMORPHIC HLDG INC$11,953,305208,500
+100.0%
0.22%
NewVERASTEM INC$11,376,6161,529,115
+100.0%
0.21%
HUM NewHUMANA INCcall$11,178,25025,000
+100.0%
0.20%
IMTX BuyIMMATICS N.V$11,157,207
+70.7%
966,829
+2.1%
0.20%
+57.8%
GDRX BuyGOODRX HLDGS INC$9,873,072
-7.1%
1,788,600
+5.2%
0.18%
-14.4%
REGN SellREGENERON PHARMACEUTICALS$9,700,290
-50.8%
13,500
-43.8%
0.18%
-54.5%
GLTO SellGALECTO INC$9,662,277
+18.7%
3,834,237
-6.3%
0.18%
+9.4%
PASG BuyPASSAGE BIO INC$9,530,263
+11.4%
10,124,576
+13.4%
0.17%
+3.0%
AKRO NewAKERO THERAPEUTICS INC$9,314,655199,500
+100.0%
0.17%
SellBRIDGEBIO PHARMA INCnote 2.250% 2/0$9,265,350
-27.9%
15,000,000
-25.0%
0.17%
-33.3%
ORIC SellORIC PHARMACEUTICALS INC$9,067,312
+15.7%
1,168,468
-15.0%
0.16%
+6.5%
GHRS SellGH RESEARCH PLCordinary shares$8,736,377
-34.1%
736,315
-55.6%
0.16%
-39.2%
THC NewTENET HEALTHCARE CORPcall$8,138,000100,000
+100.0%
0.15%
GILD NewGILEAD SCIENCES INC$7,707,000100,000
+100.0%
0.14%
NewMOONLAKE IMMUNOTHERAPEUTICSclass a ord$5,967,000117,000
+100.0%
0.11%
BuyYS BIOPHARMA CO LTDordinary shares$5,931,882
-13.7%
4,298,465
+0.0%
0.11%
-20.7%
CUTR NewCUTERA INC$5,856,823387,100
+100.0%
0.11%
CGEM SellCULLINAN ONCOLOGY INC$5,862,564
-5.3%
544,848
-10.0%
0.11%
-13.1%
SRRK BuySCHOLAR ROCK HLDG CORP$5,546,763
+34.6%
735,645
+42.8%
0.10%
+24.7%
 INVIVYD INC$5,533,920
-12.5%
5,270,4000.0%0.10%
-19.4%
HZNP  HORIZON THERAPEUTICS PUB Lput$5,142,500
-5.8%
50,0000.0%0.09%
-13.1%
NXTC  NEXTCURE INC$4,879,823
+21.6%
2,711,0130.0%0.09%
+11.4%
ALKS NewALKERMES PLC$4,738,820151,400
+100.0%
0.09%
NSPR NewINSPIREMD INC$4,669,6171,860,405
+100.0%
0.08%
ARWR NewARROWHEAD PHARMACEUTICALS IN$4,172,220117,000
+100.0%
0.08%
 VIGIL NEUROSCIENCE INC$4,219,575
-4.0%
448,8910.0%0.08%
-11.6%
 APOLLOMICS INC$3,796,475
-76.3%
662,5610.0%0.07%
-78.1%
BCAB SellBIOATLA INC$3,468,525
-66.5%
1,156,175
-70.1%
0.06%
-69.0%
CMMB  CHEMOMAB THERAPEUTICS LTDsponsored ads$2,947,275
-17.3%
2,241,2740.0%0.05%
-24.3%
SYBX  SYNLOGIC INC$2,592,898
-32.0%
6,029,9950.0%0.05%
-37.3%
RVNC BuyREVANCE THERAPEUTICS INC$2,531,000
+57.2%
100,000
+100.0%
0.05%
+43.8%
EPIX SellESSA PHARMA INC$2,489,238
-30.1%
921,940
-23.1%
0.04%
-35.7%
AFIB  ACUTUS MED INC$2,351,767
+17.8%
2,648,3860.0%0.04%
+10.3%
ELEV NewELEVATION ONCOLOGY INC$2,280,0001,500,000
+100.0%
0.04%
BOLT  BOLT BIOTHERAPEUTICS INC$1,972,480
-7.9%
1,541,0000.0%0.04%
-14.3%
TARA SellPROTARA THERAPEUTICS INC$1,846,476
-25.7%
772,584
-2.6%
0.03%
-32.7%
PHGE BuyBIOMX INC$1,639,256
+70.0%
4,553,489
+44.0%
0.03%
+57.9%
NewCALCIMEDICA INC$1,192,494297,380
+100.0%
0.02%
TGTX NewTG THERAPEUTICS INCcall$1,137,67245,800
+100.0%
0.02%
HRTX  HERON THERAPEUTICS INC$931,132
-23.2%
802,7000.0%0.02%
-29.2%
MRSN BuyMERSANA THERAPEUTICS INCcall$822,500
-5.0%
250,000
+18.7%
0.02%
-11.8%
HARP  HARPOON THERAPEUTICS INC$441,065
-4.6%
621,2180.0%0.01%
-11.1%
OMIC  SINGULAR GENOMICS SYSTEMS IN$448,779
-31.4%
540,6970.0%0.01%
-38.5%
ALT BuyALTIMMUNE INC$353,000
+65.3%
100,000
+97.6%
0.01%
+50.0%
NKTR SellNEKTAR THERAPEUTICScall$296,228
-22.7%
515,000
-5.5%
0.01%
-37.5%
ALT ExitALTIMMUNE INCcall$0-100,000
-100.0%
-0.01%
AGLE ExitAEGLEA BIOTHERAPEUTICS INC$0-1,797,221
-100.0%
-0.01%
NKTR ExitNEKTAR THERAPEUTICS$0-1,034,059
-100.0%
-0.01%
MREO ExitMEREO BIOPHARMA GROUP PLCspon ads$0-7,747,891
-100.0%
-0.11%
MRTX ExitMIRATI THERAPEUTICS INCcall$0-150,000
-100.0%
-0.11%
NTLA ExitINTELLIA THERAPEUTICS INC$0-164,627
-100.0%
-0.12%
VSTM ExitVERASTEM INC$0-16,503,237
-100.0%
-0.14%
PTGX ExitPROTAGONIST THERAPEUTICS INC$0-301,000
-100.0%
-0.14%
XBI ExitSPDR SER TRcall$0-100,000
-100.0%
-0.15%
ExitBRIDGEBIO PHARMA INCnote 2.500% 3/1$0-12,500,000
-100.0%
-0.19%
SRPT ExitSAREPTA THERAPEUTICS INCcall$0-75,000
-100.0%
-0.20%
ExitRXSIGHT INC$0-1,202,833
-100.0%
-0.39%
XBI ExitSPDR SER TRs&p biotech$0-274,000
-100.0%
-0.41%
ExitAMYLYX PHARMACEUTICALS INC$0-813,500
-100.0%
-0.47%
PGNY ExitPROGYNY INC$0-1,037,912
-100.0%
-0.65%
BLU ExitBELLUS HEALTH INC NEW$0-5,108,900
-100.0%
-0.72%
KDNY ExitCHINOOK THERAPEUTICS INC$0-2,029,300
-100.0%
-0.92%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-08-14
Signatures

The EDGAR filing(s) were signed by:

About Orbimed Advisors

Orbimed Advisors is a leading healthcare-focused investment firm that manages over $16 billion in assets. The firm was founded in 1998 by Samuel Isaly, who has over 50 years of experience in the healthcare industry. Isaly is widely regarded as a pioneer in the field of healthcare investing and has been recognized for his contributions to the industry by numerous organizations.

Orbimed Advisors has a team of over 100 professionals, including investment professionals, research analysts, and operational experts. The firm has offices in New York, San Francisco, Shanghai, and Mumbai, and invests in companies across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

The firm's investment philosophy is based on a deep understanding of the healthcare industry and a rigorous approach to due diligence. Orbimed Advisors seeks to identify companies with innovative technologies and strong management teams that have the potential to transform the healthcare landscape.

Orbimed Advisors has a strong track record of success, with numerous successful investments in companies such as Juno Therapeutics, Spark Therapeutics, and Kite Pharma. The firm's leadership team, which includes CEO Sven Borho, COO Jonathan Silverstein, and Chief Investment Officer Carl Gordon, has decades of experience in the healthcare industry and is widely respected for their expertise and insights.

Overall, Orbimed Advisors is a leading healthcare investment firm that has a proven track record of success and a deep understanding of the healthcare industry. Investors looking to gain exposure to the healthcare sector may want to consider Orbimed Advisors as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BIOGEN INC42Q3 20235.0%
VERTEX PHARMACEUTICALS INC42Q3 20233.7%
THERMO FISHER SCIENTIFIC INC42Q3 20233.2%
SINOVAC BIOTECH LTD41Q3 20237.2%
NEUROCRINE BIOSCIENCES INC41Q3 20232.7%
BOSTON SCIENTIFIC CORP40Q3 20235.6%
BRISTOL-MYERS SQUIBB CO40Q2 20235.2%
AMGEN INC40Q3 20235.5%
INTUITIVE SURGICAL INC40Q3 20233.8%
GILEAD SCIENCES INC39Q3 20235.5%

View Orbimed Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Orbimed Advisors Q2 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ikena Oncology, Inc.September 21, 20232,189,1115.2%
Galecto, Inc.September 18, 2023749,5572.8%
PMV Pharmaceuticals, Inc.August 23, 20236,563,07713.5%
Gracell Biotechnologies Inc.August 11, 20237,641,5318.0%
Xtant Medical Holdings, Inc.August 03, 202373,114,59256.7%
Turnstone Biologics Corp.July 24, 20233,099,26513.4%
Prelude Therapeutics IncMay 24, 202315,716,64228.6%
VectivBio Holding AGMay 24, 20235,156,5617.7%
Fusion Pharmaceuticals Inc.May 16, 20232,930,6704.6%
Verona Pharma plcMay 16, 20233,777,7784.8%

View Orbimed Advisors's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-26
42024-04-23
42024-04-18
42024-04-15
3/A2024-04-12
SC 13D/A2024-04-12
42024-04-05
SC 13D/A2024-04-04
32024-04-03
SC 13D2024-03-28

View Orbimed Advisors's complete filings history.

Compare quarters

Export Orbimed Advisors's holdings